Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.890
-0.200 (-4.89%)
At close: Apr 28, 2026, 4:00 PM EDT
3.914
+0.024 (0.62%)
After-hours: Apr 28, 2026, 4:22 PM EDT
Agenus Revenue
In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth. Agenus had revenue of $34.20M in the quarter ending December 31, 2025, with 27.45% growth.
Revenue (ttm)
$114.20M
Revenue Growth
+10.37%
P/S Ratio
1.33
Revenue / Employee
$1,409,827
Employees
81
Market Cap
149.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alpha Cognition | 10.22M |
| Fate Therapeutics | 6.65M |
| Alps Group | 3.74M |
| Humacyte | 2.04M |
| Oramed Pharmaceuticals | 2.00M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
AGEN News
- 7 days ago - Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - Business Wire
- 7 days ago - Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs - Business Wire
- 11 days ago - Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Business Wire
- 25 days ago - Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - Business Wire
- 27 days ago - Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - Business Wire
- 4 weeks ago - Agenus Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - Business Wire
- 6 weeks ago - Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - Business Wire